Drug

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes
Academic conferenceClinical trial results

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes

GenFleet Therapeutics (HKG: 2595) announced preliminary clinical data from its Phase Ia dose‑escalation study of investigational GFH276, an oral molecular‑glue Pan‑RAS inhibitor, in patients with pretreated RAS‑mutant solid tumors –…

CStone's Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

CStone’s Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial resultsNovartis

Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis

ADC / XDCBreakthrough therapy

SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC

Changchun High & New Technology IndustriesClinical trial filings

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States
EisaiMarket launch

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Show More